Top Oakland, CA Biotech Companies (25)
Shiru is creating the next generation of sustainable ingredients.
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com
Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.
Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Executive Relentlessly
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.
Science is an early stage company developing technologies for a range of serious unmet medical needs. We are unafraid to take difficult technical risks, secure in the knowledge that with a clear understanding of what we are doing and with support from powerful modern tools, more progress is possible than might be immediately obvious.
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
We discover the 1 in a million 10,000x faster. Harnessing evolution means giving nature the time and space to find complex solutions. Current technology falls fall short of the scale required to accelerate this process. The current state of the art is to rely on technology like liquid-handling robotics to look for a 1-in-a-million solution using a method that can only search through thousands of samples. At Triplebar, we measure the effect of billions of mutations. We oversample the genome every day and use this capacity to quickly find solutions to the greatest problems we face.
Andes empowers biology to enable positive action against climate change
We exist to ensure all patients have access to early cardiac and pulmonary disease detection and high quality care that improves and extends their lives. We believe the ability to listen is the ability to care. Which is why we’re dedicated to providing healthcare professionals with industry leading digital tools to hear and understand their patients’ hearts and lungs — allowing them to detect with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Hear clearly. Care confidently.
Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
Kyverna is a cell therapy company engineering and developing a new class of curative living medicines for inflammatory and autoimmune diseases. Using its SmarTcell™ approach which includes synReg-T cell and synNotch CAR-T technology platforms, Kyverna reprograms T cells to target and selectively suppress or eliminate autoreactive immune cells. The company’s goal is to develop therapies that are selective, potent and durable to tame autoimmunity. We build interdisciplinary teams that bring a broad range of experiences and scientific expertise together to develop medicines that will free patients from the siege of autoimmune diseases and bring curiosity for exploring and creating the unknown. Our commitment to our employees is to foster an open, supportive, and inclusive environment where we create opportunities for individuals to learn and grow to their full potential at every level. synNotch is a trademark of Gilead/Kite.
We are a science and material innovation company rethinking biology and reimagining the world. A World Economic Forum Tech Pioneer, we partner with nature to create never-before imagined materials and products across industries – from agriculture to electronics, consumer care to pharmaceuticals, and more. Our company creates sustainable materials that are in use today, delivering value for Fortune 1000 companies with over $1 billion worth of products using Zymergen microbial innovations sold to date. At Zymergen we make tomorrow.
We create materials at the intersection of art, nature and biotechnology using mycelium, one of the earth’s most regenerative resources. Our mission is to create a platform for the highest quality materials using Fine Mycelium™. Our first product, Reishi™ offers our partners in fashion an option for leather that is neither animal nor plastic, yet uncompromising in quality and aesthetic expression. Today, our team is growing in order to scale and deliver Reishi to an even broader range of partners in fashion, footwear and beyond. Together, we’re working towards a world where mycelium enables resilient, creative solutions for any industry dependent on animal and petroleum-derived products. Founded by artists and innovators, MycoWorks is building an inclusive, mission-driven team of people, and a culture where all employees belong. We are passionate learners who are proud of the breakthrough materials we’re bringing to the world. Join our growing team, and let’s grow the future of materials.
Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform’s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.
Pattern Ag is developing a recommendation and product discovery platform centered around a deep understanding of soil. We are leveraging advances in genomics, robotics, and high-resolution agronomic data to build this knowledge, in service of improving farm profitability
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
